Pancreatic IPMN – precancerous lesion or harmless incidental finding?
Intraductal papillary mucinous neoplasia (IPMN) is a cystic change in the pancreas and is considered a premalignant lesion, meaning it is not cancer at first, but can develop into an invasive tumor over time.
Importance and Risk
Not all IPMNs become malignant. The decisive factor is the risk classification based on imaging and clinical characteristics. A distinction is made between absolute indications for surgery, relative indications for surgery, and IPMNs that require observation.
Absolute indications for surgery (high risk of cancer):
- Main duct enlargement greater than 10 mm
- Contrast-enhancing wall nodule
- Jaundice caused by the cyst
In these cases, surgery is recommended.
Relative indications for surgery:
- Cyst size ≥ 40 mm
- Main duct 5–9.9 mm
- Growth or symptoms
Surgery is also often performed in these cases, depending on the individual situation.
Why isn’t every IPMN operated on?
This is a very important and often misunderstood point. The guidelines explicitly recommend monitoring instead of surgery if:
- there are no high-risk characteristics
- the patient is symptom-free
- and the cyst is small
This is because many IPMNs remain stable and would never develop into cancer. Therefore, surgery is not always justified. Genetic counseling is recommended when IPMN is diagnosed. The GITZ works together with the Onkozentrum Zürich or Hirslanden Precise in this regard.
How is monitoring carried out?
The standard procedure is:
- MRI and/or endosonography
- initially every 6–12 months
- then usually annually
Monitoring is carried out for life, as long as the patient is fit for surgery. MRI is the preferred method, as it provides the best visualization of the ducts.
Prognosis
The prognosis depends heavily on whether cancer has already developed. Without invasive cancer development, a normal life expectancy can be expected. After surgery in the early stages, it is almost always curable. In the case of invasive carcinoma, the prognosis is the same as for classic pancreatic carcinoma.
Therefore, proper monitoring is crucial.